Searched for
ADUCANUMAB
New theory suggests Alzheimer's might not be primarily a brain disease, could just be an autoimmune conditionScientists believe that beta-amyloid is not an abnormally produced protein.- World Alzheimer’s Day: 45 mins of daily exercise, 7-8 hrs of sleep, protein-rich diet can keep disease at bayAir pollution and other environmental factors can also speed up the onset of Azhiemer’s disease.
- Nasdaq and S&P 500 end at record highs; Dow ralliesWith massive fiscal stimulus helped the U.S. economy grow at a 6.4% annualized rate in the first quarter, investors have been banking on an...
- Nasdaq, S&P 500 scale new peaks as jobs recovery gains tractionData showed fewer weekly jobless claims pointed to a steady recovery in the labor market.
- FDA approves much-debated Alzheimer's drug panned by expertsThe new drug, which Biogen developed with Japan's Eisai Co., did not reverse mental decline, only slowing it in one study. The drug is give...
- US FDA okays Biogen Alzheimer’s drugUS regulators on Monday approved Biogen’s aducanumab as the first treatment to address an underlying cause of Alzheimer’s disease despite c...
- Dow Jones flat as investors await US inflation dataInvestors remained on the fence ahead of key inflation data later this week.
- FDA panel reviews first new Alzheimer's drug in 2 decadesA panel of outside experts meets Friday to advise the Food and Drug Administration on aducanumab, a drug from Cambridge, Massachusetts-base...
- Nasdaq ends at record high as Wall Street rises with tech sharesApple Inc and Microsoft Corp provided the biggest boosts to the Dow and S&P 500, with the S&P 500 technology index up 1.6% and leading sect...
- Dow Jones rises on rebound hopes despite jump in virus casesThe Dow Jones Industrial Average was up 121.80 points, or 0.47 per cent, at 26,011.98.
- Nikkei closes flat even as chip makers make a buzzChip equipment makers jumped, tracking a rise in US tech shares overnight.
Load More
